医学
地塞米松
血糖性
围手术期
观察研究
糖尿病
荟萃分析
随机对照试验
麻醉
恶心
内科学
重症监护医学
内分泌学
作者
José Luis López-Bonilla,Jeanette B Rodriguez-Torres,Gilbert L Verar,Jill A Mason-Nguyen,Chad B Moore
标识
DOI:10.1016/j.jopan.2021.10.005
摘要
Abstract
Purpose
P Perioperative administration of single-dose dexamethasone helps reduce postoperative nausea and vomiting, inflammation, and pain. However, it is unclear which dose achieves these effects while minimizing the hyperglycemic impact in patients with diabetes. The purpose of this review was to elucidate the most appropriate perioperative dose of dexamethasone for diabetic patients, and whether it is necessary to withhold it in patients with poor glycemic control. Design
A systematic review. Methods
A literature search using PubMed and Cochrane Database of Systematic Reviews revealed 17 potential evidence sources. Eight sources met the inclusion criteria. Sources included one systematic review with meta-analysis, one randomized control trial, and six observational studies. Findings
Evidence suggests diabetic patients who receive dexamethasone perioperatively are more likely to develop postoperative hyperglycemia, with a maximum blood glucose increase of 30 to 45 mg/dL in the first 24 hours following a single dose. One study described increased blood glucose levels with escalating doses, but no other sources have supported that finding. The available studies were markedly heterogeneous in both design and proportion of diabetic subjects included, and most were of low quality. Conclusions
There is not enough evidence to quantify the hyperglycemic effect of commonly used dexamethasone doses, and rigorous studies are needed to inform practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI